Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis

References

• HamMMossACMesalamine in the treatment and maintenance of remission of ulcerative colitisExpert Rev Clin Pharmacol2012511312322390554
   PubMed Web of Science ®Google Scholar
• LoftusEVClinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influencesGastroenterology20041261504151715168363
   PubMed Web of Science ®Google Scholar
• LakatosPLRecent trends in the epidemiology of inflammatory bowel diseases: up or down?World J Gastroenterol2006126102610817036379
   PubMed Web of Science ®Google Scholar
• DignassALindsayJOSturmASecond European evidence-based consensus on the diagnosis and management of ulcerative colitis: current managementJ Crohns Colitis20126991103023040451
   PubMed Web of Science ®Google Scholar
• DignassAPreissJCAustDEUpdated German guideline on diagnosis and treatment of ulcerative colitis, 2011Z Gastroenterol20114912761341 German21866493
   PubMed Web of Science ®Google Scholar
• KornbluthASacharDBUlcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters CommitteeAm J Gastroenterol201010550152320068560
   PubMed Web of Science ®Google Scholar
• SvartzNSalazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparationActa Med Scand194211557590
   Google Scholar
• SutherlandLMacDonaldJKOral 5-aminosalicylic acid for induction of remission in ulcerative colitisCochrane Database Syst Rev20062CD000543
   Google Scholar
• Azad KahnAKPirisJTrueloveSCAn experiment to determine the active therapeutic moiety of sulphasalazineLancet1977310892895
   Google Scholar
• van HeesPABakkerJHvan TongerenJHEffect of sulphapyridine, 5-aminosalicyclic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazineGut1980216326356107263
   PubMed Web of Science ®Google Scholar
• KlotzUMaierKFischerCTherapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn’s diseaseN Engl Med J198030314991502
   PubMed Web of Science ®Google Scholar
• NielsenOHSulfasalzine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel diseaseScand J Gastroenterol1982173893936127793
   PubMed Web of Science ®Google Scholar
• PeppercornMASulfasalazine. Pharmacology, clinical use, toxicity, and related new drug developmentAnn Intern Med19841013773866147110
   PubMed Web of Science ®Google Scholar
• NielsenOHBondesenSKinetics of 5-aminosalicylic acid after jejunal instillation in manBr J Clin Pharmacol1983167387406661362
   PubMed Web of Science ®Google Scholar
• MyersBEvansDNRhodesJMetabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tractGut1987281962003557190
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBSystematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitisAliment Pharmacol Ther200317294212492730
   PubMed Web of Science ®Google Scholar
• SandbornWJOral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?J Clin Gastroenterol200842338344
   PubMed Web of Science ®Google Scholar
• EganLJMaysDCHuntoonCJInhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activityJ Biol Chem1999274264482645310473604
   PubMed Web of Science ®Google Scholar
• LiptaySBachemMHackerGInhibition of nuclear factor κB and induction of apoptosis in T-lymphocytes by sulfasalazineBr J Pharmacol19991281361136910602313
   PubMed Web of Science ®Google Scholar
• BantelHBergCViethMMesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitisAm J Gastroenterol2000953452345711151876
   PubMed Web of Science ®Google Scholar
• DesreumauxPGhoshSReview article: mode of action and delivery of 5-aminosalicylic acid – new evidenceAliment Pharm Ther200624Suppl 129
   PubMed Web of Science ®Google Scholar
• KlotzUThe pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid)Arzneimittelforschung201262535822344548
   PubMed Web of Science ®Google Scholar
• DesreumauxPUnderstanding the mechanism of 5-ASA in treating colonic inflammationGastroenterol Hepatol20084319320
   PubMedGoogle Scholar
• BertinBDubuquoyLColombelJFDesreumauxPPPAR-gamma in ulcerative colitis: a novel target for interventionCurr Drug Targets2013141501150723651165
   PubMed Web of Science ®Google Scholar
• LichtensteinGRKammMAReview article: 5-aminosalicylate formulations for the treatment of ulcerative colitis – methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosaAliment Pharmacol Ther20082866367318532992
   PubMed Web of Science ®Google Scholar
• CampieriMLanfranchiGABazzocchiGTreatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemasLancet1981282412702716114321
   PubMed Web of Science ®Google Scholar
• HarrisMSLichtensteinGRReview article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitisAliment Pharmacol Ther201133996100921385194
   PubMed Web of Science ®Google Scholar
• FordACKhanKJAchkarJPEfficacy of oral vs topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysisAm J Gastroenterol201210716717622108446
   PubMed Web of Science ®Google Scholar
• CampieriMCorbelliCGionchettiPSpread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitisDig Dis Sci199237189018971473437
   PubMed Web of Science ®Google Scholar
• GhoshSShandAFergusonAUlcerative colitisBMJ20003201119112310775225
   PubMed Web of Science ®Google Scholar
• SeiboldFFournierNBeglingerCSwiss IBD cohort study group. Topical therapy is underused in patients with ulcerative colitisJ Crohns Colitis20148566323566922
   PubMed Web of Science ®Google Scholar
• FarrellRJPeppercornMAEquimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?Am J Gastroenterol2002971283128512094839
   PubMed Web of Science ®Google Scholar
• ForbesACartwrightAMarchantSMcIntyrePNewtonMReview article: Oral, modified-release mesalazine formulations – proprietary versus genericAliment Pharmacol Ther2003171207121412755834
   PubMed Web of Science ®Google Scholar
• WildingIRKenyonCJHooperGGastroinestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachetAliment Pharmacol Ther20001416316910651656
   PubMed Web of Science ®Google Scholar
• FarupPGHinterleitnerTALukasMMesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitisInflamm Bowel Dis2001723724211515850
   PubMed Web of Science ®Google Scholar
• KruisWKlugmannTDuffelmeyerCDetailed analysis of factors determining patients adherence to therapy in ulcerative colitisUEG J20131Suppl 1A224 (P342)
   Google Scholar
• ForbesAAl-DamlujiAAshworthSMulticentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitisAliment Pharmacol Ther2005211099110415854171
   PubMed Web of Science ®Google Scholar
• WildingIRBehrensCTardifSJCombined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjectsAliment Pharmacol Ther2003171153116212752352
   PubMed Web of Science ®Google Scholar
• RaedlerABehrensCBiasPMesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis – results from a randomized-controlled trialAliment Pharmacol Ther2004201353136315606398
   PubMed Web of Science ®Google Scholar
• BrunnerMGreinwaldRKletterKGastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs tablets in male healthy volunteersAliment Pharmacol Ther2003171163116912752353
   PubMed Web of Science ®Google Scholar
• KruisWBar-MeirSFeherJThe optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamineClin Gastroenterol Hepatol20031364315017515
   PubMed Web of Science ®Google Scholar
• LakatosPLUse of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: is there anything new under the sun?World J Gastroenerol20091517991804
   PubMed Web of Science ®Google Scholar
• BrunnerMAssandriRKletterKGastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulationAliment Pharmacol Ther20031739540212562452
   PubMed Web of Science ®Google Scholar
• PranteraCViscidoABianconeLA new oral delivery system for 5-ASA: preliminary clinical findings for MMXInflamm Bowel Dis20051142142715867580
   PubMed Web of Science ®Google Scholar
• SutherlandLMacDonaldJKOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisCochrane Database Syst Rev20062CD00054416625537
   PubMedGoogle Scholar
• ItoHIidaMMatsumotoTDirect comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized studyInflamm Bowel Dis2010161567157420049950
   PubMed Web of Science ®Google Scholar
• PranteraCKohnACampieriMClinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with AsacolAliment Pharmacol Ther20093090891819678813
   PubMed Web of Science ®Google Scholar
• FeaganBGMacdonaldJKOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisCochrane Database Syst Rev201210CD00054423076890
   PubMed Web of Science ®Google Scholar
• FeaganBGMacdonaldJKOral 5-aminosalicylic acid for induction of remission in ulcerative colitisCochrane Database Syst Rev201210CD00054323076889
   PubMed Web of Science ®Google Scholar
• KaneSHuoDMagnantiKA pilot feasibility study on once daily versus conventional dosing mesalamine for maintenance of ulcerative colitisClin Gastroenterol Hepatol2003117017315017487
   PubMed Web of Science ®Google Scholar
• RobinsonAReview article: improving adherence to medication in patients with inflammatory bowel diseaseAliment Pharmacol Ther200827Suppl 191418307644
   PubMed Web of Science ®Google Scholar
• HawthorneABRubinGGhoshSReview article: medication non-adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapiesAliment Pharmacol Ther2008271157116618384664
   PubMed Web of Science ®Google Scholar
• KaneSVCohenRDAikensJEPrevalence of non-adherence with maintenance mesalamine in quiescent ulcerative colitisAm J Gastroenterol20019629292933
   PubMed Web of Science ®Google Scholar
• ShaleMJRileySAStudies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel diseaseAliment Pharmacol Ther20031819119812869079
   PubMed Web of Science ®Google Scholar
• LakatosPLPrevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it?World J Gastroenterol2009154234423919750566
   PubMed Web of Science ®Google Scholar
• KaneSVRobinsonAReview article: understanding adherence to medication in ulcerative colitis – innovative thinking und evolving conceptsAliment Pharmacol Ther2010321051105820815833
   PubMed Web of Science ®Google Scholar
• KaneSHuoDAikensJMedication non-adherence and outcomes of patients with quiescent ulcerative colitisAm J Med2003114394312543288
   PubMed Web of Science ®Google Scholar
• van HeesPAMvan TongerenJHMCompliance to therapy in patients on a maintenance dose of sulfasalazineJ Clin Gastroenterol198243333366126499
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther2001231296131011558866
   PubMed Web of Science ®Google Scholar
• HussainFNAjjanRAKapurKMoustafaMRileySAOnce versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parametersAliment Pharmacol Ther200115536211136278
   PubMed Web of Science ®Google Scholar
• GandiaPIdierIHouinGIs once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteersJ Clin Pharmacol20074733434217322145
   PubMed Web of Science ®Google Scholar
• DasKMEastwoodMAMcManusJPAdverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotypeN Engl Med J1973289491495
   PubMed Web of Science ®Google Scholar
• FordACKhanKJSandbornWJOnce daily dosing vs conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysisAm J Gastroenterol20111062070207721894226
   PubMed Web of Science ®Google Scholar
• HayllarJBjarnasonISulphasalazine in ulcerative colitis: in memoriam?Gut1991324624631674925
   PubMed Web of Science ®Google Scholar
• KruisWJonaitisLPokrotnieksJRandomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitisAliment Pharmacol Ther20113331332221138455
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJKornbluthADelayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trialAm J Gastroenterol20051002478248516279903
   PubMed Web of Science ®Google Scholar
• LichtensteinGRRamseyDRubinDTRandomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs 2.4 g/day in endoscopic mucosal healing – ASCEND I and II combined analysisAliment Pharmacol Ther20113367267821255059
   PubMed Web of Science ®Google Scholar
• SandbornWJRegulaJFeaganBGDelayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitisGastroenterology20091371934194319766640
   PubMed Web of Science ®Google Scholar
• KammMASandbornWJGassullMOnce-daily, high-concentration MMX mesalamine in active ulcerative colitisGastroenterology2007132667517241860
   PubMed Web of Science ®Google Scholar
• Shire plcAnnual Reports from 2008 to 2012 Available from: http://www.shire.com/shireplc/en/investors/reportsAccessed August 4, 2013
   Google Scholar
• StallmachAHäuserWL‘hoestHDie chronisch entzündlichen Darmerkrankungen Morbus Crohn und Colitis ulcerosa: Herausforderungen an die Versorgung. [The inflammatory bowel diseases Crohns disease and ulcerative colitis: Challenges for health care]RepschlägerUSchulteCOsterkampNBarmer GEK Gesundheitswesen aktuell 2012. [Barmer GEK public health care up to date 2012]Düsseldorf, Germany37 Grad GmbH286309 German
   Google Scholar
• GlaeskeGSchicktanzCSchriftenreihe zur Gesundheitsanalyse, Band 14. [Monograph series for analysis of health. Volume 14]Barmer GEK Arzneimittelreport 2012 Available from: https://presse.barmer-gek.de/barmer/web/Portale/Presseportal/Subportal/Infothek/Studien-und-Reports/Arzneimittelreport/Einstieg-Arzneimittelreport.htmlAccessed July 30, 2013 German
   Google Scholar
• BlumensteinITackeWFilmannNIntegrated management of patients with chronic inflammatory bowel disease in the Rhine-Main region: results of the first integrated health-care project IBD in GermanyZ Gastroenterol201351613618 German23696113
   PubMed Web of Science ®Google Scholar
• Istock Analyst [homepage on the Internet]Warner Chilcott Plc: numerous sources of potential upside2202013 Available from: http://www.istockanalyst.com/finance/story/6300463/warner-chilcott-plc-numerous-sources-of-potentialupsideAccessed August 11, 2013
   Google Scholar
• Warner Chilcott plcForm 10-K for December 31, 2012 Available from: https://tickerpot.com/symbol/wcrx/1323854/topic/asacolAccessed August 11, 2013
   Google Scholar
• KaneSHoldermanWJacquesPMiodekTOnce daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trialPatient Prefer Adherence2008225325819920971
   PubMedGoogle Scholar
• KammMALichtensteinGRSandbornWJRandomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitisGut20085789390218272546
   PubMed Web of Science ®Google Scholar
• DignassAUBokemeyerBAdamekHMesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitisClin Gastroenterol Hepatol2009776276919375519
   PubMed Web of Science ®Google Scholar
• SandbornWJKorzenikJLashnerBOnce-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitisGastroenterology20101381286129620064514
   PubMed Web of Science ®Google Scholar
• HawthorneABStensonRGillespieDOne-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitisInflamm Bowel Dis2012181885189322081522
   PubMed Web of Science ®Google Scholar
• LichtensteinGRKammMABodduPEffect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderate active ulcerative colitisClin Gastroenterol Hepatol200759510217234558
   PubMed Web of Science ®Google Scholar
• KruisWKiudelisGRaczIOnce daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trialGut20095823324018832520
   PubMed Web of Science ®Google Scholar
• FlourieBHagegeHTucatGRandomised clinical trial: once- vs twice-daily prolonged-release mesalazine for active ulcerative colitisAliment Pharmacol Ther20133776777523451806
   PubMed Web of Science ®Google Scholar
• FeaganBGMacDonaldJKOnce daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysisInflamm Bowel Dis2012181785179422644954
   PubMed Web of Science ®Google Scholar
• LeifeldLPfützerRMorgensternJMesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis – a pooled analysisAliment Pharmacol Ther2011341115112221923715
   PubMed Web of Science ®Google Scholar
• BrooksAJLoboAJAre mesalazine granules superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis?Aliment Pharmacol Ther20123519319422150535
   PubMed Web of Science ®Google Scholar
• SandbornWJKammMALichtensteinGRMMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trialsAliment Pharmacol Ther20072620521517593066
   PubMed Web of Science ®Google Scholar
• KaneSVSumnerMSolomonDJenkinsMTwelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions databaseDig Dis Sci2011563463347021879279
   PubMed Web of Science ®Google Scholar
• YenLWuJHodgkinsPLCohenRDNicholMBMedication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitisJ Manag Care Pharm20121870171223206213
   PubMed Web of Science ®Google Scholar
• LachaineJYenLBeaucheminCHodgkinsPMedication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ databaseBMC Gastroenterol2013132323363459
   PubMed Web of Science ®Google Scholar
• JacksonCAClatworthyJRobinsonAHorneRFactors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic reviewAm J Gastroenterol201010552553919997092
   PubMed Web of Science ®Google Scholar
• RansfordRAJLangmanMJSSulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of MedicinesGut20025153653912235076
   PubMed Web of Science ®Google Scholar
• D’HaensGvan BodegravenAAMesalazine is safe for the treatment of IBDGut20045315514684596
   PubMed Web of Science ®Google Scholar
• LoftusEVJrKaneSVBjorkmanDSystematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitisAliment Pharmacol Ther20041917918914723609
   PubMed Web of Science ®Google Scholar
• FeaganBGChandeNMacDonaldJKAre there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from cochrane reviewsInflamm Bowel Dis2013192031204023811638
   PubMed Web of Science ®Google Scholar
• SchroederKWReview: is mesalamine safe?Gastroenterol Hepatol20073878879
   PubMedGoogle Scholar
• van StaaTPTravisSLeufkensHGLoganRF5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic studyGastroenterology20041261733173915188168
   PubMed Web of Science ®Google Scholar
• GisbertJPGonzález-LamaYMatéJ5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic reviewInflamm Bowel Dis20071362963817243140
   PubMed Web of Science ®Google Scholar
• SoKBewsheaBWHeapGA5-Aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel diseaseGastroenterology2013144Suppl 1112 (A638)23041322
   PubMed Web of Science ®Google Scholar